Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
Holding MRNA?
Track your performance easily
MRNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.55 - $170.47
Previous Close$71.99
Volume4.28M
Average Volume (3M)4.39M
Market Cap
$27.67B
Enterprise Value$20.43B
Total Cash (Recent Filing)$8.49B
Total Debt (Recent Filing)$1.24B
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Oct 31, 2024EPS Estimate
-$1.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.38
Shares Outstanding384,396,030
10 Day Avg. Volume7,051,576
30 Day Avg. Volume4,388,115
Standard Deviation0.26
R-Squared0.11
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.36
Price to Sales (P/S)5.33
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.04
Enterprise Value/Gross Profit9.91
Enterprise Value/Ebitda-5.38
Forecast
1Y Price Target
$104.53Price Target Upside49.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
Moderna News
PremiumMarket News
VOO ETF Update, 9/16/2024 
Bulls Say, Bears Say
Bulls Say
Clinical TrialsModerna’s mRNA cancer vaccine has progressed into the late clinical stage, leading the competition in this space.
Financial OutlookThe updated financial framework gives confidence on the impact of ongoing cost-cutting measures and path to breakeven in 2028.
Product LaunchRegulatory filing for mRNA-1083 gives MRNA first mover advantage in the COVID/flu combo vaccine market.
Bears Say
Financial PerformanceRevenue estimates for 2025 are lowered mainly due to expected lower ex-US Spikevax/COVID sales.
Guidance & ProfitabilityLong-awaited guidance cut sees profitability pushed out to 2028 from 2026, but risk remains alongside concerns the company may need to raise capital to achieve the new guidance.
Regulatory IssuesLack of FDA support for accelerated approval of mRNA-4157 in adjuvant melanoma will pressure estimates considerably in the near term.
---
Ownership Overview
14.68% Insiders
22.82% Mutual Funds
44.82% Other Institutional Investors
17.68% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $62.55 and its highest was $170.47 in the past 12 months.
What is Moderna’s market cap?
Currently, no data Available
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Aug 01, 2024. The company reported -$3.33 earnings per share for the quarter, beating the consensus estimate of -$3.348 by $0.018.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -$1.85.
How many shares outstanding does Moderna have?
Moderna has 384,396,030 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$3.33 in its last earnings report, beating expectations of -$3.348. Following the earnings report the stock price went down -21.012%.
Which hedge fund is a major shareholder of Moderna?
Among the largest hedge funds holding Moderna’s share is Theleme Partners Llp. It holds Moderna’s shares valued at 858M.
---
Moderna Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$104.53 (49.63% Upside)
$104.53 (49.63% Upside)
Blogger Sentiment
Neutral
MRNA Sentiment 57%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 6.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.17%
12-Months-Change
Fundamentals
Return on Equity
-40.94%
Trailing 12-Months
Asset Growth
-28.35%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
MRNA Company Deck
---
MRNA Earnings Call
Q2 2024
0:00 / 0:00
---
MRNA Revenue Breakdown
52.54% Rest of World
27.67% U.S.
19.79% Europe
---
MRNA Stock 12 Month Forecast
Average Price Target
$104.53
▲(49.63% Upside)
Technical Analysis
Best Analysts Covering MRNA
1 Year
1 Year Success Rate
29/37 ratings generated profit
1 Year Average Return
-13.64%
reiterated a sell rating 6 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 78.38% of your transactions generating a profit, with an average return of -13.64% per trade.
---